Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pre-surgical Evaluation of MK-2206 in Patients With Operable Invasive Breast Cancer

NCT01319539 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT01319539
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01319539 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pre-surgical Evaluation of MK-2206 in Patients With Operable Invasive Breast Cancer
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Terminated
Start date
April 30, 2011
Completion date
July 31, 2013
Enrollment
12 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

estrogen receptor negative, estrogen receptor positive, her2/neu negative, her2/neu positive, progesterone receptor negative, progesterone receptor positive, stage ia breast cancer, stage ib breast cancer, stage iia breast cancer, stage iib breast cancer, stage iiia breast cancer, stage iiib breast cancer, stage iiic breast cancer, triple-negative breast carcinoma